Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/eci.13315 http://scihub22266oqcxt.onion/10.1111/eci.13315 32535890!7323025!32535890     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Invest 2020 ; 50 (9): e13315 Nephropedia Template TP {{tp|p=32535890|t=2020. Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak |pdf=|usr=}}{{32535890}} gab.com Text Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak JO: Eur J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32535890 #FOAvip BACKGROUND: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS AND METHODS: Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management. RESULTS: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. CONCLUSIONS: These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic. Twit Text FOAVip Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak ????Eur J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=32535890 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32535890 #FOAvip English Wikipedia <ref>{{Cite pmid|32535890}}</ref> Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak #MMPMID32535890 Tagliamento M; Spagnolo F; Poggio F; Soldato D; Conte B; Ruelle T; Barisione E; De Maria A; Del Mastro L; Di Maio M; Lambertini M Eur J Clin Invest 2020[Sep]; 50 (9): e13315 PMID32535890show ga BACKGROUND: During COVID-19 outbreak, oncological care has been reorganized. Patients with cancer have been reported to experience a more severe COVID-19 syndrome; moreover, there are concerns of a potential interference between immune checkpoint inhibitors (ICIs) and SARS-CoV-2 pathogenesis. MATERIALS AND METHODS: Between 6 and 16 May 2020, a 22-item survey was sent to Italian physicians involved in administering ICIs. It aimed at exploring the perception about SARS-CoV-2-related risks in cancer patients receiving ICIs, and the attitudes towards their management. RESULTS: The 104 respondents had a median age of 35.5 years, 58.7% were females and 71.2% worked in Northern Italy. 47.1% of respondents argued a synergism between ICIs and SARS-CoV-2 pathogenesis leading to worse outcomes, but 97.1% would not deny an ICI only for the risk of infection. During COVID-19 outbreak, to reduce hospital visits, 55.8% and 30.8% opted for the highest labelled dose of each ICI and/or, among different ICIs for the same indication, for the one with the longer interval between cycles, respectively. 53.8% of respondents suggested testing for SARS-CoV-2 every cancer patient candidate to ICIs. 71.2% declared to manage patients with onset of dyspnoea and cough as infected by SARS-CoV-2 until otherwise proven; however, 96.2% did not reduce the use of steroids to manage immune-related toxicities. The administration of ICIs in specific situations for different cancer types has not been drastically conditioned. CONCLUSIONS: These results highlight the uncertainties around the perception of a potential interference between ICIs and COVID-19, supporting the need of focused studies on this topic. |Adult[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/statistics & numerical data[MESH] |Coronavirus Infections/diagnosis/*epidemiology[MESH] |Disease Outbreaks/*statistics & numerical data[MESH] |Female[MESH] |Humans[MESH] |Immunocompromised Host[MESH] |Immunologic Factors/*administration & dosage[MESH] |Italy[MESH] |Male[MESH] |Medical Oncology/methods[MESH] |Middle Aged[MESH] |Neoplasms/*drug therapy/epidemiology/immunology[MESH] |Outcome Assessment, Health Care[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*epidemiology[MESH] |Risk Assessment[MESH]Italian survey on managing immune checkpoint inhibitors in oncology du(epmc).pdf DeepDyve Pubget Overpricing